Aquestive Therapeutics, Inc.
Financials
Valuation Metrics
Aquestive Therapeutics, Inc.'s Market Cap is $486M. At end of 2025 it was $788M. Ranked #2746 of 3,116 in US market (top 88%), #1199 of 1,472 on NASDAQ (top 81%), #216 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $486M | US#2,746/3,116 Sec#216/265 |
| Revenue | $54M | US#2,735/3,116 Sec#143/265 |
| Net Income | $-78M | US—/3,116 Sec—/265 |
| Total Assets | $132M | US#3,031/3,116 Sec#255/265 |
| Net Assets | $-57M | US#2,943/3,116 Sec#247/265 |
| Employees | 147 | US#2,536/3,116 Sec#144/265 |
| Value | ||
| P/S | 8.99x | US#2,665/3,116 Sec#113/265 |
| FCF Yield | -9.45% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -59.22% | US#3,012/3,116 Sec#230/265 |
| Op. Margin | -97.52% | US#2,711/3,116 Sec#124/265 |
| Revenue Growth | 22.56% | US#605/3,116 Sec#72/265 |
| Financial Health | ||
| Total Debt | $59M | US#2,567/3,116 Sec#149/265 |
| FCF | $-46M | US#2,515/3,116 Sec#112/265 |
| Cash | $98M | US#2,239/3,116 Sec#176/265 |
| Current Ratio | 7.19x | US#342/3,116 Sec#106/265 |
| Performance | ||
| 1Y Return | -41.82% | US#2,717/3,116 Sec#224/265 |
| 1M Return | -16.31% | US#2,704/3,116 Sec#213/265 |
| From 52W High | -43.43% | US#2,429/3,116 Sec#176/265 |
| 1Y MDD | -55.44% | US#2,638/3,116 Sec#189/265 |
| Trading | ||
| Volume | 2,017,500 shares | US#905/3,116 Sec#86/265 |
| Trading Value | $8M | US#2,404/3,116 Sec#197/265 |
| Per Share | ||
| EPS | $-0.62 | US—/3,116 Sec—/265 |
| BPS | $-0.45 | US—/3,116 Sec—/265 |
Company Info
Aquestive Therapeutics, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing products to address significant unmet medical needs across both the United States and international markets. The company's commercialized portfolio includes: Sympazan, an oral soluble film formulation of clobazam for individuals with Lennox-Gastaut syndrome. Suboxone, a sublingual film containing buprenorphine and naloxone, indicated for the treatment of opioid dependence. Zuplenz, an oral soluble film of ondansetron, used to manage nausea and vomiting associated with chemotherapy and post-operative recovery. Azstarys, a once-daily medication for attention deficit hyperactivity disorder. Aquestive maintains a robust proprietary pipeline of drug candidates. These include: Libervant, a buccal soluble film formulation of diazepam currently in development for the treatment of seizures. Exservan, an oral soluble film of riluzole, aimed at treating amyotrophic lateral sclerosis (ALS). Within its complex molecule pipeline, the company is advancing: AQST-108, a sublingual film designed to deliver systemic epinephrine for conditions other than anaphylaxis. AQST-305, a sublingual film formulation of octreotide for managing acromegaly. AQST-109, an orally administered epinephrine product candidate intended for the emergency treatment of severe allergic reactions, including anaphylaxis. Furthermore, Aquestive Therapeutics played a role in the development of KYNMOBI, a sublingual film formulation of apomorphine, used to address episodic "off" periods in patients with Parkinson's disease. Established in 2004, Aquestive Therapeutics, Inc. is headquartered in Warren, New Jersey.